Human Induced Pluripotent Stem Cell-derived Cardiomyocytes As an in Vitro Model for Coxsackievirus B3-induced Myocarditis and Antiviral Drug Screening Platform
Overview
Authors
Affiliations
Rationale: Viral myocarditis is a life-threatening illness that may lead to heart failure or cardiac arrhythmias. A major causative agent for viral myocarditis is the B3 strain of coxsackievirus, a positive-sense RNA enterovirus. However, human cardiac tissues are difficult to procure in sufficient enough quantities for studying the mechanisms of cardiac-specific viral infection.
Objective: This study examined whether human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) could be used to model the pathogenic processes of coxsackievirus-induced viral myocarditis and to screen antiviral therapeutics for efficacy.
Methods And Results: hiPSC-CMs were infected with a luciferase-expressing coxsackievirus B3 strain (CVB3-Luc). Brightfield microscopy, immunofluorescence, and calcium imaging were used to characterize virally infected hiPSC-CMs for alterations in cellular morphology and calcium handling. Viral proliferation in hiPSC-CMs was quantified using bioluminescence imaging. Antiviral compounds including interferonβ1, ribavirin, pyrrolidine dithiocarbamate, and fluoxetine were tested for their capacity to abrogate CVB3-Luc proliferation in hiPSC-CMs in vitro. The ability of these compounds to reduce CVB3-Luc proliferation in hiPSC-CMs was consistent with reported drug effects in previous studies. Mechanistic analyses via gene expression profiling of hiPSC-CMs infected with CVB3-Luc revealed an activation of viral RNA and protein clearance pathways after interferonβ1 treatment.
Conclusions: This study demonstrates that hiPSC-CMs express the coxsackievirus and adenovirus receptor, are susceptible to coxsackievirus infection, and can be used to predict antiviral drug efficacy. Our results suggest that the hiPSC-CM/CVB3-Luc assay is a sensitive platform that can screen novel antiviral therapeutics for their effectiveness in a high-throughput fashion.
Mohamed H, Elberry Y, Magdy H, Ismail M, Michael M, Eltayeb N Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 40072553 DOI: 10.1007/s00210-025-03962-x.
Cardiomyopathy: pathogenesis and therapeutic interventions.
Huang S, Li J, Li Q, Wang Q, Zhou X, Chen J MedComm (2020). 2024; 5(11):e772.
PMID: 39465141 PMC: 11502724. DOI: 10.1002/mco2.772.
Tatekoshi Y, Chen C, Shapiro J, Chang H, Blancard M, Lyra-Leite D Elife. 2024; 13.
PMID: 39331464 PMC: 11434618. DOI: 10.7554/eLife.95867.
Macrophages enhance contractile force in iPSC-derived human engineered cardiac tissue.
Lock R, Graney P, Tavakol D, Nash T, Kim Y, Sanchez Jr E Cell Rep. 2024; 43(6):114302.
PMID: 38824644 PMC: 11254687. DOI: 10.1016/j.celrep.2024.114302.
Biodegradable suture development-based albumin composites for tissue engineering applications.
Naser M, Sayed A, Abdelmoez W, El-Wakad M, Abdo M Sci Rep. 2024; 14(1):7912.
PMID: 38575715 PMC: 10995150. DOI: 10.1038/s41598-024-58194-5.